{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:53:52Z","timestamp":1790276032517,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013238","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000}}],"reference-count":72,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013238.pub2","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T08:40:56Z","timestamp":1589272856000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Anti-epidermal growth factor receptor therapy for glioblastoma in adults"],"prefix":"10.1002","volume":"2020","author":[{"given":"Adrian","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology; Royal North Shore Hospital; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malmaruha","family":"Arasaratnam","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology; Royal North Shore Hospital; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Lok Hang","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology; Royal North Shore Hospital; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Khasraw","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, The University of Sydney; Camperdown Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viive M","family":"Howell","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology; Royal North Shore Hospital; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology; Royal North Shore Hospital; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD013238.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1371\/journal.pone.0156369","article-title":"Multi-center randomized phase II study comparing cediranib plus gefitinib with cediranib plus placebo in subjects with recurrent\/progressive glioblastoma","volume":"11","author":"Brown","year":"2016","journal-title":"PLOS One"},{"issue":"16","key":"10.1002\/14651858.CD013238.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-14-3220","article-title":"A multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma patients","volume":"21","author":"Lee","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD013238.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"v17","DOI":"10.1093\/neuonc\/nou237.38","article-title":"A randomized phase II trial of vandetanib (ZD6474) in combination with carboplatin versus carboplatin alone in adults with recurrent glioblastoma","volume":"16","author":"McNeill","year":"2014","journal-title":"Neuro-Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013238.pub2-BIB0004|cit4","first-page":"430","article-title":"Phase I\/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma","volume":"17","author":"Reardon","year":"2015","journal-title":"Neuro-Oncology"},{"key":"10.1002\/14651858.CD013238.pub2-BIB0005|cit5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1140","article-title":"Rindopepimut with Bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial","volume":"Feb 7","author":"Reardon","year":"2020","journal-title":"Clinical Cancer Research"},{"issue":"8","key":"10.1002\/14651858.CD013238.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1200\/JCO.2008.17.5984","article-title":"Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034","volume":"27","author":"den Bent","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013238.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"pii: noz222","DOI":"10.1093\/neuonc\/noz222","article-title":"Intellance2\/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma","volume":"Nov 20","author":"den Bent","year":"2019","journal-title":"Neuro-Oncology"},{"issue":"10","key":"10.1002\/14651858.CD013238.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013238.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ejca.2014.12.019","article-title":"A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma","volume":"51","author":"Westphal","year":"2015","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD013238.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s13566-014-0166-3","article-title":"A phase II study of surgical excision, temozolomide, radiotherapy, and anti-EGFR radioimmunotherapy (EXTRA) as adjuvant therapy in high-grade gliomas","volume":"3","author":"Daugherty","year":"2014","journal-title":"Journal of Radiation Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013238.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3892\/etm.2012.555","article-title":"Nimotuzumab prolongs survival in patients with malignant gliomas: a phase I\/II clinical study of concomitant radiochemotherapy with or without nimotuzumab","volume":"4","author":"Hong","year":"2012","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"9","key":"10.1002\/14651858.CD013238.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/annonc\/mdp032","article-title":"Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma","volume":"20","author":"Neyns","year":"2009","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013238.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/neuonc\/nou348","article-title":"A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study","volume":"17","author":"Schuster","year":"2015","journal-title":"Neuro-Oncology"},{"key":"10.1002\/14651858.CD013238.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"S585","DOI":"10.1016\/S0959-8049(16)31619-7","article-title":"GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation","volume":"51","author":"Sepulveda","year":"2015","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD013238.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/1471-2407-13-299","article-title":"Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial","volume":"13","author":"Solomon","year":"2013","journal-title":"BMC Cancer"},{"issue":"18","key":"10.1002\/14651858.CD013238.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"iv44","DOI":"10.1093\/neuonc\/now188.152","article-title":"Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM)","volume":"18","author":"Van Den Bent","year":"2016","journal-title":"Neuro-Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013238.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/neuonc\/not247","article-title":"Phase I\/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02","volume":"16","author":"Wen","year":"2014","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013238.pub2-BIB0018|cit18","first-page":"29","article-title":"Simultaneous radiotherapy and radioimmunotherapy of malignant gliomas with anti-EGFR antibody labelled with iodine 125","volume":"5","author":"Wygoda","year":"2002","journal-title":"Nuclear Medicine Review. Central & Eastern Europe"},{"issue":"3","key":"10.1002\/14651858.CD013238.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/hyb.2006.25.125","article-title":"Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors","volume":"25","author":"Wygoda","year":"2006","journal-title":"Hybridoma (2005)"},{"key":"10.1002\/14651858.CD013238.pub2-BIB0020|cit20","unstructured":"AbbVie Inc and Radiation Therapy Oncology Group A study of ABT-414 in subjects with newly diagnosed glioblastoma with epidermal growth factor receptor amplification (Intellance 1) clinicaltrials.gov\/show\/NCT02573324"},{"key":"10.1002\/14651858.CD013238.pub2-BIB0021|cit21","unstructured":"Australian Institute of Health and Welfare Cancer in Australia 2017. Cancer Series no. 101 www.aihw.gov.au\/reports\/cancer\/cancer-in-australia-2017\/contents\/table-of-contents"},{"issue":"6","key":"10.1002\/14651858.CD013238.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00401-015-1432-1","article-title":"Glioblastoma: pathology, molecular mechanisms and markers","volume":"129","author":"Aldape","year":"2015","journal-title":"Acta Neuropathologica"},{"issue":"12","key":"10.1002\/14651858.CD013238.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene"},{"issue":"4","key":"10.1002\/14651858.CD013238.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/cncr.28968","article-title":"Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date","volume":"121","author":"Bastien","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"10.1002\/14651858.CD013238.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"issue":"7","key":"10.1002\/14651858.CD013238.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/annonc\/mdh257","article-title":"Pharmacological background of EGFR targeting","volume":"15","author":"Castillo","year":"2004","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013238.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy\u2013temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013238.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-pathol-011110-130324","article-title":"Glioblastoma: from molecular pathology to targeted treatment","volume":"9","author":"Cloughesy","year":"2014","journal-title":"Annual Review of Pathology"},{"issue":"4","key":"10.1002\/14651858.CD013238.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s12253-014-9833-3","article-title":"Molecular heterogeneity of glioblastoma and its clinical relevance","volume":"20","author":"Eder","year":"2014","journal-title":"Pathology & Oncology Research"},{"issue":"8","key":"10.1002\/14651858.CD013238.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013238.pub2-BIB0031|cit31","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2015"},{"issue":"10","key":"10.1002\/14651858.CD013238.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.4161\/cc.4.10.2105","article-title":"Biomarkers to predict response to epidermal growth factor receptor inhibitors","volume":"4","author":"Haas-Kogan","year":"2005","journal-title":"Cell Cycle"},{"issue":"9839","key":"10.1002\/14651858.CD013238.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD013238.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1158\/1078-0432.CCR-04-1737","article-title":"Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients","volume":"11","author":"Heimberger","year":"2005","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD013238.pub2-BIB0035|cit35","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"87","key":"10.1002\/14651858.CD013238.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"re6","DOI":"10.1126\/scisignal.287re6","article-title":"Oncogenic EGFR signaling networks in glioma","volume":"2","author":"Huang","year":"2009","journal-title":"Science Signaling"},{"issue":"1","key":"10.1002\/14651858.CD013238.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3390\/cancers6010226","article-title":"Glioblastoma multiforme: a look inside its heterogeneous nature","volume":"6","author":"Inda","year":"2014","journal-title":"Cancers"},{"issue":"17","key":"10.1002\/14651858.CD013238.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013238.pub2-BIB0039|cit39","first-page":"196","volume-title":"Evaluation of Chemotherapeutic Agents","author":"Karnofsky","year":"1949"},{"issue":"1","key":"10.1002\/14651858.CD013238.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11060-016-2094-0","article-title":"Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial","volume":"128","author":"Khasraw","year":"2016","journal-title":"Journal of Neuro-oncology"},{"issue":"2","key":"10.1002\/14651858.CD013238.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/2046-4053-2-81","article-title":"Assessing and presenting summaries of evidence in Cochrane Reviews","volume":"23","author":"Langendam","year":"2013","journal-title":"Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013238.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/nop\/npv018","article-title":"Prophylactic anticonvulsants for gliomas: a seven-year retrospective analysis","volume":"2","author":"Lapointe","year":"2015","journal-title":"Neuro-Oncology Practice"},{"issue":"7","key":"10.1002\/14651858.CD013238.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013238.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1055\/s-0033-1357483","article-title":"Brain neoplasms and coagulation","volume":"39","author":"Magnus","year":"2013","journal-title":"Seminars in Thrombosis & Hemostasis"},{"key":"10.1002\/14651858.CD013238.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/2046-4053-3-82","article-title":"A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation","volume":"3","author":"Meader","year":"2014","journal-title":"Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD013238.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013238.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/neuonc\/nou356","article-title":"Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study","volume":"17","author":"Nabors","year":"2015","journal-title":"Neuro-Oncology"},{"key":"10.1002\/14651858.CD013238.pub2-BIB0048|cit48","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0, November 2017 https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"issue":"4","key":"10.1002\/14651858.CD013238.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.3892\/ol.2017.5770","article-title":"Incidence trends in high-grade primary brain tumors in males and females","volume":"13","author":"Nilsson","year":"2017","journal-title":"Oncology Letters"},{"key":"10.1002\/14651858.CD013238.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"22477","DOI":"10.1038\/srep22477","article-title":"Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma","volume":"6","author":"Parker","year":"2016","journal-title":"Scientific Reports"},{"issue":"suppl 4","key":"10.1002\/14651858.CD013238.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"iv73","DOI":"10.1093\/neuonc\/nos197","article-title":"Thromboembolic disease in patients with high-grade glioma","volume":"14","author":"Perry","year":"2012","journal-title":"Neuro-Oncology"},{"key":"10.1002\/14651858.CD013238.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.thromres.2015.11.018","article-title":"Increased risk of venous thromboembolism in patients with brain tumors: a systematic review and meta-analysis","volume":"137","author":"Qian","year":"2016","journal-title":"Thrombosis Research"},{"issue":"7","key":"10.1002\/14651858.CD013238.pub2-BIB0053|cit53","first-page":"965","article-title":"Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma","volume":"19","author":"Reardon","year":"2017","journal-title":"Neuro-Oncology"},{"key":"10.1002\/14651858.CD013238.pub2-BIB0054|cit54","unstructured":"Review Manager (RevMan) The Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"31","key":"10.1002\/14651858.CD013238.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2010.28.6963","article-title":"Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma","volume":"28","author":"Sampson","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013238.pub2-BIB0056|cit56","unstructured":"Scott NW Fayers PM Aaronson NK Bottomley A de Graeff A Groenvold M on behalf of the EORTC Quality of Life Group EORTC QLQ-C30 reference values, 2008 www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/reference_values_manual2008.pdf"},{"issue":"25","key":"10.1002\/14651858.CD013238.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"10.1002\/14651858.CD013238.pub2-BIB0058|cit58","first-page":"6962","article-title":"Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme","volume":"63","author":"Shinojima","year":"2003","journal-title":"Cancer Research"},{"issue":"10","key":"10.1002\/14651858.CD013238.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1073\/pnas.1219747110","article-title":"Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics","volume":"110","author":"Sottoriva","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"10","key":"10.1002\/14651858.CD013238.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncology"},{"issue":"10","key":"10.1002\/14651858.CD013238.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"23","key":"10.1002\/14651858.CD013238.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD013238.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ejca.2010.01.012","article-title":"An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients","volume":"46","author":"Taphoorn","year":"2010","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD013238.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.thromres.2012.09.020","article-title":"Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients","volume":"131","author":"Thaler","year":"2013","journal-title":"Thrombosis Research"},{"issue":"12","key":"10.1002\/14651858.CD013238.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/neuonc\/nou106","article-title":"Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas","volume":"16","author":"Thaler","year":"2014","journal-title":"Neuro-oncology"},{"issue":"1","key":"10.1002\/14651858.CD013238.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1212\/WNL.0b013e318204a3af","article-title":"The paradoxical effect of bevacizumab in the therapy of malignant gliomas","volume":"76","author":"Thompson Eric","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD013238.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"1","key":"10.1002\/14651858.CD013238.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1002\/14651858.CD013238.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD013238.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40263-017-0456-6","article-title":"EGFR as a target for glioblastoma treatment: an unfulfilled promise","volume":"31","author":"Westphal","year":"2017","journal-title":"CNS drugs"},{"issue":"10","key":"10.1002\/14651858.CD013238.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1093\/neuonc\/now091","article-title":"Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy\/temozolomide for newly diagnosed glioblastoma","volume":"18","author":"Wick","year":"2016","journal-title":"Neuro-Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013238.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:17:31Z","timestamp":1767687451000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013238.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":72,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013238.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,12]]}}}